الفهرس 
coverOnly 14 pages are availabe for public view
 |  | from | 158 |  |  |
| | | from | 158 | | |
Abstract
Cancer is one of the most common causes of death, taking nearly 7 million lives each year worldwide. Due to the low selectivity and the high side effects seen by the traditional chemotherapeutic agents, tremendous efforts are being exerted to get more selective anticancer agents. This required thorough study of signal transduction pathways that holds the promise of efficacy with minimal toxicity. Vascular endothelial growth factor receptor (VEGFR) was identified as one of the efficient targets for evolving new anticancer agents having the desired selectivity on cancerous cells. By targeting VEGFR, angiogenesis is greatly inhibited leading to the death of the tumor cells. 2. Rationale and Design: In our current study, new quinoxaline derivatives were explored for its activity against VEGFR-2. The targeted compounds were designed as type-II inhibitors based on comprehensive SAR study. Synthesis of the designed quinoxaline-based compounds was accomplished and their structures were confirmed by various spectral and micro analytical data.